CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|July 1, 2004
New molecular entity: Trospium
The parasympatholytic action of trospium reduces the tonus of smooth muscle in the bladder by antagonizing the effect of acetylcholine on muscarinic receptors. Trospium was approved on May 28, 2004, for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Advertisement
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
The purchase comes as the "big 3" drug wholesalers are coming under scrutiny for their market dominance and the possible perils of vertical integration.
High prices and cutbacks in ACA and Medicaid coverage leave many patients unable to medical bills.
In this discussion, Heather Burrell-Ward, M.D., provides an overview of her recent study that found TMS aimed at the default mode network improved processing speed in schizophrenia.
Rand researchers identify standardizing supplemental benefits, limiting the number of plans an insurer can market and reforming broker commissions as policy proposals that would benefit beneficiaries while not harming the government or the plans.
Reimagine Care and Dan Nardi scale CAR-T programs with remote cancer care, AI triage and nurses, as the Cureety partnership tackles staffing and access.
Biosimilars can cost $600 a month versus $6,000 for branded rivals, but PBM rebate incentives push formularies toward pricier drugs, says Christine Johnston.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medical debt burdens more than 1 in 4 adults in the U.S., survey finds
2
Christine Johnston on why biosimilars are losing formulary ground
3
McKesson, private equity firm buy home infusion company, Option Care Health
4
A conversation with Heather Burrell Ward, M.D., about developing TMS as a treatment for the cognitive symptoms of schizophrenia
5